Skip Navigation


Annals of Oncology Advance Access originally published online on April 6, 2006
Annals of Oncology 2006 17(11):1615-1619; doi:10.1093/annonc/mdl060
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
17/11/1615    most recent
mdl060v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hassan, R
Right arrow Articles by Verschraegen, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hassan, R
Right arrow Articles by Verschraegen, C
Related Collections
Right arrow 2006 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

reviews

Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference

R Hassan1,*, R Alexander1, K Antman1, P Boffetta2, A Churg3, D Coit4, P Hausner5, R Kennedy6, H Kindler7, M Metintas8, L Mutti9, M Onda1, H Pass10, A Premkumar1, V Roggli11, D Sterman12, P Sugarbaker13, R Taub14 and C Verschraegen15

1 National Cancer Institutes of Health, Bethesda, USA
2 International Agency for Research on Cancer, Lyon, France
3 University of British Columbia, Canada
4 Memorial Sloan-Kettering Cancer Center
5 University of Maryland
6 Texas Tech University Health Sciences Center
7 University of Chicago, Chicago, USA
8 Osmangazi University, Turkey
9 Local Health Unit 11, Vercelli, Italy
10 Karmanos Cancer Institute
11 Duke University Medical Center
12 University of Pennsylvania
13 Washington Hospital Center
14 Columbia University
15 University of New Mexico, USA

* Correspondence to: Dr R. Hassan, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5116, Bethesda, MD 20892–4264 USA. Tel: +1 (301) 451-8742; Fax: +1 (301) 402-1344; E-mail: hassanr{at}mail.nih.gov

Peritoneal mesothelioma is a rare cancer of the peritoneum with about 250 new cases diagnosed each year in the United States. It is the second most common site for mesothelioma development and accounts for 10–20% of all mesotheliomas diagnosed in the United States. A meeting sponsored by the NIH Office of Rare Diseases was held in Bethesda, Maryland on September 13 and 14, 2004. The objective of this meeting was to review the epidemiology, biology and current surgical and medical management of peritoneal mesothelioma. In addition, the meeting also discussed clinical and pre-clinical evaluation of novel treatments for mesothelioma as well as ongoing laboratory research to better understand this disease. This report summarizes the proceedings of the meeting as well as directions for future clinical and basic research.

Key words: cancer, mesothelioma, peritoneal


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.